[1] ANDERSON G P. Formoterol: Pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator[J]. Life sciences, 1993, 52 26: Pages 2145-2160. DOI:
10.1016/0024-3205(93)90729-m[2] N. DECKER. Effects of N-aralkyl substitution of β-agonists on α- and β-adrenoceptor subtypes: pharmacological studies and binding assays[J]. Journal of Pharmacy and Pharmacology, 1982, 34 2: 107-112. DOI:
10.1111/j.2042-7158.1982.tb04195.x[3] HARUHITO SUGIYAMA MD. The effect of formoterol on the late asthmatic phenomena in guinea pigs[J]. Journal of Allergy and Clinical Immunology, 1992, 89 4: Pages 858-866. DOI:
10.1016/0091-6749(92)90442-5[4] MARC L DECRAMER. The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease.[J]. International Journal of Chronic Obstructive Pulmonary Disease, 2013, 8: 53-64. DOI:
10.2147/copd.s39018[5] DONALD P TASHKIN Gary T F. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease.[J]. Respiratory Research, 2013, 14: 49. DOI:
10.1186/1465-9921-14-49[6] ADRIANA YOCK CORRALES Mike S Manuel Soto Martinez. Management of severe asthma in children.[J]. Australian family physician, 2011, 40 1-2: 35-38.